Reflex method for the detection of prostate cancer
CA 2311512 A1 · Owner: Allard, William Jeffrey · Inventors: Allard, William Jeffrey
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A method for aiding in the detection of prostate cancer in male human patients, e.g. for differentiating prostate cancer from the normal condition and from benign, prostate diseases such as prostate hypertrophy (BPH) and prostatitis by a , reflex, method in which complexed prostate specific antigen (cPSA) is first measured in a, blood sample from a male patient and if the patient's cPSA blood level is greater than, an upper limit of normal (e.g. between about 2 and about 4 ng/mL) total PSA , (tPSA), is then measured in the sample and the proportion of the measured tPSA amount that is, the measured cPSA amount is determined. The cut-off for the proportion of cPSA to, tPSA can be set to …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 14, 2000. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended June 14, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 14, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.